(Nasdaq: ACON) Launches Statewide Initiative to Deliver Advanced Personal Injury and Workers Compensation Diagnostics with AI Technology
Aclarion, Inc. (Nasdaq: ACON), a healthcare technology company utilizing biomarkers and AI algorithms to improve the diagnosis of chronic low back pain, announced a new partnership aimed at applying its Nociscan technology to the personal injury and workers compensation market in New Jersey. Led by orthopedic surgeon Dr. Justin Kubeck of Ocean Pain and Spine in Toms River, NJ, this initiative will establish a statewide network of providers using Nociscan to better evaluate low back pain cases within these legal systems.
Key Highlights:
- Strategic Partnership: Dr. Justin Kubeck will spearhead efforts to create a network of New Jersey providers using Nociscan to provide objective diagnostics for patients with chronic low back pain in the personal injury and workers compensation sectors.
- Significant Financial Impact: Personal injury claims involving the neck and back in New Jersey have an average settlement of $918,967, while work-related accidents leading to similar injuries have an average settlement of $148,750. Accurate diagnostics play a critical role in these cases.
- Objective Evaluation Tool: Nociscan’s ability to measure biomarkers in lumbar discs provides an objective diagnostic tool that can improve the evaluation process and help providers formulate and defend treatment plans in legal settings.
- Expansion Potential: Following its success in New Jersey, Aclarion plans to expand the program to other markets across the U.S., replicating this targeted approach in the personal injury and workers compensation sectors.
Ryan Bond, Chief Strategy Officer of Aclarion, noted, “This partnership is an important step toward expanding the use of Nociscan’s advanced biomarker technology in the personal injury and workers compensation market. We believe the objective data provided by Nociscan can have a significant impact on both patient care and legal outcomes.”
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Disclaimer
This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…
